Search Results
Your search for all items matches 37107 pages
Showing 1 - 50
Yelena Y. Janjigian, MD, FASCO, on CLARITY-Gastric 01: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center—a co-chair of a Presidential Symposium at the ESMO Congress 2026—reviews results from the phase III trial that looked at the CLDN18.2-targeting antibody-drug conjugate sonesitatug vedotin vs investigator’s choice of therapy...
Elizabeth Smyth, MD, on Esophageal/GEJ Cancer: Pembrolizumab or Placebo Plus Concurrent Definitive Chemoradiotherapy
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses data from the phase III KEYNOTE-975 study, which examined definitive chemoradiotherapy with or without pembrolizumab in patients with previously untreated locally advanced unresectable esophageal and...
Elizabeth Smyth, MD, on Gastric/GEJ Cancer: Novel CLDN18.2-Targeting ADC
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, reviews results from the phase III G-HOPE-001 trial, which evaluated the CLDN18.2-targeted antibody-drug conjugate arcotatug tavatecan in previously treated patients with gastric or gastroesophageal junction (GEJ)...
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
For patients with relapsed or refractory follicular lymphoma, the timing of progression is one of the factors Peter A. Riedell, MD, considers when choosing the next treatment. A long first remission may support another course of chemoimmunotherapy, but progression within 24 months of starting...
Current Public Knowledge Rates on Alcohol and Cancer Risks
According to a nationally representative survey conducted in October by the Annenberg Public Policy Center of the University of Pennsylvania, the number of Americans aware of the connection between alcohol consumption and an increased risk of cancer has increased to 58%. The policy center has been ...
Phase III VOLGA Trial: Durvalumab/Tremelimumab/Enfortumab Vedotin Improves Outcomes in Bladder Cancer
In the phase III VOLGA trial, researchers evaluated the use of perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy....
Study Reveals Distinct Cellular and Genetic Differences in Early-Onset Colorectal Cancer
Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation, along with researchers at Dana-Farber Cancer Institute and the Broad Institute, have identified biological differences in colorectal tumors that may help explain why the disease can behave more aggressively ...
OptiTROP-Lung06: A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
In patients with advanced PD-L1–negative nonsquamous non–small cell lung cancer (NSCLC) without targetable genomic alterations, first-line treatment with the Trop-2–directed antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab demonstrated a significant progression-free survival...
ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer. The guideline replaces ASTRO’s 2018 recommendations and reflects a...
Selpercatinib, Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
Researchers from Vall d’Hebron University Hospital presented advances in targeted therapies for patients with thyroid cancer during the ESMO Congress 2026. Updated results of the phase III LIBRETTO-531 trial showed durable benefits with selpercatinib compared with existing targeted therapies for...
Financial Navigation Program May Help Reduce Cancer-Related Financial Hardship
A financial navigation intervention was associated with significant reductions in financial toxicity among patients with cancer across rural and nonrural oncology practices, according to findings from the Lessening the Impact of Financial Toxicity (LIFT) trial reported by Wheeler et al in the...
Disitamab Vedotin Plus Tislelizumab Shows Activity in Very High–Risk Non–Muscle-Invasive Bladder Cancer
Treatment with the anti-ERBB2 antibody-drug conjugate disitamab vedotin plus the anti–PD-1 immune checkpoint inhibitor tislelizumab-jsgr showed evidence of antitumor activity in patients with transurethrally unresectable, ERBB2-positive, very high–risk non–muscle invasive bladder cancer, according...
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
In 2024, ASCO updated its guideline for the integration of palliative care in oncology, which recommends that clinicians refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams beginning early in the course of a patient’s disease ...
Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs
In the AYA-RISE trial, the addition of an electronic chatbot–based communication tool to a cancer predisposition clinic visit improved knowledge of cancer risk by age 30 compared with the visit alone, without increasing psychological distress. The findings were published by Kamihara et al in JAMA...
TALENT: Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Neoadjuvant treatment with the HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki (T-DXd), given alone, with endocrine therapy, or followed by chemotherapy, produced pathologic complete response rates (pCR) in the single digits among patients with hormone receptor (HR)-positive,...
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
Findings from a substudy of the phase III PROTEUS trial provided further support for the use of perioperative apalutamide and androgen-deprivation therapy (ADT) before and after surgery for patients with high-risk localized and locally advanced prostate cancer, according to results presented at the ...
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
In patients with extensive-stage small cell lung cancer (SCLC), tarlatamab-dlle, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than 8 months, more than tripled progression-free survival, and reduced the risk of death by 58%...
F-SHARP Trial Evaluates Focal Salvage Brachytherapy and Genomic Risk Stratification in Recurrent Prostate Cancer
According to findings from the phase I/II F-SHARP trial reported by Solanki et al in the Journal of Clinical Oncology, dose-escalated focal salvage high–dose rate brachytherapy demonstrated favorable disease control with low rates of severe toxicity in patients with locally recurrent prostate...
Sanjiv S. Gangaram-Panday, PhD, on Esophageal Cancer: Active Surveillance vs Standard Surgery After Neoadjuvant Chemoradiotherapy
Sanjiv S. Gangaram-Panday, PhD, of Erasmus University, presents 5-year outcomes from the Surgery As Needed for Oesophageal Cancer (SANO) trial. The study previously demonstrated that active surveillance is noninferior to standard surgery in terms of 2-year overall survival in patients with a...
James J. Harding, MD, on Advanced Biliary Tract Cancer: Ivonescimab/Chemotherapy vs Durvalumab/Chemotherapy
The phase III HARMONi-GI1 trial is evaluating the efficacy and safety of ivonescimab, a PD-1/VEGF bispecific antibody, plus chemotherapy vs durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer. At the ESMO Congress 2026, invited discussant James J. Harding, MD,...
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
Patients with advanced melanoma achieved deep and durable responses after receiving the tumor-infiltrating lymphocyte (TIL) therapy lifileucel alongside the immune checkpoint inhibitor pembrolizumab as a first-line treatment, according to results from a new clinical trial. Approximately two-thirds...
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
Machine learning models using routine clinical data may be able to identify individuals at higher risk of developing several common cancers, according to findings from an international study presented at the ESMO Congress 2026 (Abstract 280RO). “For selected cancers, these models could serve as a...
Sacituzumab Tirumotecan Extends PFS, OS in Advanced/Recurrent Endometrial Cancer
Sacituzumab tirumotecan extended both progression-free and overall survival compared with standard chemotherapy in patients with advanced or recurrent endometrial cancer, according to findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 trial presented at the ESMO Congress 2026 (Abstract...
Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors
Expert histopathologic evaluation followed by molecular analyses when necessary provided a definitive diagnosis in more than 97% of patients with ambiguous primary cutaneous melanocytic tumors, according to findings from a prospective cohort study reported by Ebbelaar et al in the Journal of...
Is Enucleation a Safe Alternative to Pancreatoduodenectomy for Benign or Low-Grade Pancreatic Head Tumors?
A multicenter retrospective cohort study published by Yao et al in JAMA Surgery found that although pancreatic enucleation was associated with a higher rate of clinically relevant postoperative pancreatic fistula than pancreatoduodenectomy, it was linked to fewer major complications, less delayed...
Impact of Digital Breast Tomosynthesis on Invasive Interval Breast Cancer Rate
Breast cancer screening with digital breast tomosynthesis plus synthesized two-dimensional mammography resulted in fewer invasive interval breast cancers over 2 years than standard digital mammography, although the difference did not reach statistical significance. Weigel et al reported the...
Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson...
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
The addition of consolidation radiotherapy to first-line systemic anticancer therapy resulted in better local disease control and prolonged progression-free survival compared with systemic therapy alone in patients with synchronous oligometastaic non–small cell lung cancer (NSCLC) without an...
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC
Patients with previously treated advanced KRAS G12C–mutant non–small cell lung cancer (NSCLC) had improved progression-free and overall survival and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of...
Shannon N. Westin, MD, on Advanced or Recurrent Endometrial Cancer: DUO-E/GOG-3041/ENGOT-EN10
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, reviews interim overall survival and safety results from a randomized phase III study evaluating durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with advanced/recurrent...
FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate Cancers
Today, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor talazoparib (Talzenna) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation–naive or –sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR)...
Brian M. Slomovitz, MD, on dMMR Advanced or Recurrent Endometrial Cancer: KEYNOTE-C93/GOG-3064/ENGOT-en15
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, discusses results from a phase III, randomized, open-label study of first-line pembrolizumab vs carboplatin/paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial carcinoma (Abstract LBA12).
GLP-1 RA Use Lower Among Adults With Both Diabetes and a History of Cancer
Adults with diabetes and a history of cancer were less likely to report current use of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) than those without a cancer history, despite having higher rates of cardiovascular and kidney disease. Olinto Linares-Perdomo, PhD, and colleagues...
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase III EMT2 trial presented at the European...
Triplet Therapy With Abiraterone Improves Long-Term OS in Metastatic Castration-Sensitive Prostate Cancer
Abiraterone acetate added to androgen-deprivation therapy and docetaxel resulted in a significant overall survival benefit compared with standard-of-care therapy alone in patients with de novo metastatic castration-sensitive prostate cancer, according to long-term findings from the phase III...
High-Risk Melanoma: Personalized mRNA Vaccine Plus Immunotherapy May Benefit Outcomes After Surgery
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract...
Presidential Symposium Highlights in Small Cell Lung Cancer
Three phase III studies in small cell lung cancer (SCLC) were among the notable findings presented during a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer held in Seoul. The studies addressed important questions...
Real-World Data Are Not Necessarily Real-World Evidence
Real-world data (RWD) provide raw material from which real-world evidence (RWE) is generated, but the two terms are not synonymous. Over the past decade, RWD and RWE have become increasingly prominent in oncology. A search of the 2016 ASCO Annual Meeting abstracts identified 48 with terms “real...
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
On October 16, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high...
Of Note in the Oncology Community: September/October 2026
Areej R. El-Jawahri, MD, FASCO, was named by ASCO as the 2026 recipient of the Joseph Simone Quality Care Award. She accepted her award and presented her keynote lecture at the 2026 ASCO Quality Care Symposium held recently in Boston. Dr. El-Jawahri is Co-Director of the Cancer Outcomes Research...
Three Decades of AYA Cancer Survivorship
Growing up, I was a curious, empathetic kid with an interest in biology. When I was diagnosed with non-Hodgkin lymphoma 2 months before I turned 15, those qualities shaped how I engaged with my care. I asked questions, wanted to understand what was happening in my body, and built strong...
Robert A. Kyle, MD, Renowned Expert in Myeloma, Dies at 98
The International Myeloma Foundation (IMF) shared news on the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly-revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
The final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome were recently presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany...
Mammography Screening for Recurrence After a Diagnosis of Breast Cancer
Nahleh and colleagues recently updated ASCO guidelines regarding the frequency of breast screening following a diagnosis of primary breast cancer and recommended annual mammography for most patients.1 Presumably, the benefit of mammography will come from finding recurrences earlier, e.g., smaller...
Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening
Among medically underserved adults who smoked and were referred for lung cancer screening, the addition of financial incentives to usual care and free pharmacotherapy significantly increased rates of sustained tobacco abstinence compared with usual care alone or usual care plus free...
Patient-Friendly Research Summaries Spotlight Advances in Pancreatic Cancer
The science and practice of translation is about more than moving discoveries from the lab to the clinic. It also helps break down barriers to access so crucial developments in cancer care can reach patients and improve outcomes all over the world. To help you spread the word about these...
ASCO Issues Its First Living Guideline on Systemic Treatment of Recurrent Ovarian Cancer
In June 2026, an ASCO Expert Panel voted to approve ASCO’s first Living Guideline on systemic treatment of ovarian cancer recurrence.1 The continuously updated, evidence-based guideline addresses patients with epithelial ovarian cancer, primary peritoneal carcinoma, and fallopian tube carcinoma,...
Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials
A recent study by researchers from The Univetsity of Texas MD Anderson Cancer Center, ASCO, and collaborating institutions evaluated the national landscape of geographic access to active triple-negative breast cancer clinical trials. The findings—published by Amin et al in Breast Cancer Research...
Data From Pivotal Trials Lead to Recent Drug Approvals in Colorectal, Breast, RCC, and CLL/SLL Malignancies
In September and October, the U.S. Food and Drug Administration (FDA) released statements regarding the Agency’s approval of a number of oncology drug products across several solid tumors and hematologic malignancies. A summary of these approvals is provided here. Combination Approved in dMMR Colon ...
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
The addition of metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic breast cancer, according to findings from the randomized phase II portion of the NRG-BR002 trial reported by Chmura et al...
